Financial Performance - The company's operating revenue for 2023 reached ¥760,042,604.88, representing a 29.65% increase compared to ¥586,231,829.02 in 2022[19]. - Net profit attributable to shareholders for 2023 was ¥134,729,838.37, an 86.06% increase from ¥72,411,406.83 in 2022[19]. - The net cash flow from operating activities increased by 184.02% to ¥114,846,570.24 in 2023, up from ¥40,435,604.36 in 2022[19]. - Basic earnings per share for 2023 were ¥2.24, a 65.93% increase compared to ¥1.35 in 2022[19]. - Total assets at the end of 2023 amounted to ¥1,366,819,029.33, reflecting a 17.76% increase from ¥1,160,719,180.61 at the end of 2022[19]. - The operating cost for 2023 was ¥528,940,660.79, with a gross margin of 30.41%, which is an increase of 3.12% from the previous year[58]. - Employee compensation accounted for 82.38% of the total operating costs, amounting to ¥435,749,266.44, reflecting a year-on-year increase of 17.74%[61]. - The company reported a decrease in overseas revenue by 25.07%, with total overseas sales of ¥2,862,413.54 in 2023[57]. - The company reported a significant increase in revenue for the first half of 2023, reaching approximately 1.2 billion yuan, representing a year-over-year growth of 25%[123]. - The company reported a revenue increase of 15% year-over-year, reaching 1.2 billion yuan in Q2 2023[121]. Dividends and Shareholder Returns - The company plans to distribute a cash dividend of 1.66 RMB per 10 shares to all shareholders, based on a total of 61,160,000 shares[3]. - The company distributed a cash dividend of 0.68 RMB per 10 shares, totaling 10,152,560 RMB for the first three quarters of 2023[168]. - The cumulative undistributed profits at the end of 2023 amounted to 332,036,485.74 RMB[172]. - The company plans to distribute a cash dividend of 1.66 RMB per 10 shares, totaling 10,152,560 RMB, and to increase capital by 3 shares for every 10 shares held, resulting in a total of 18,348,000 new shares[173]. Corporate Governance - The company maintains complete independence from its controlling shareholder in terms of assets, personnel, finance, organization, and business operations[132]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[130]. - The company has established a dedicated internal audit department to oversee the implementation of internal control systems and the accuracy of financial information[131]. - The company has a complete and independent financial accounting system, allowing for autonomous financial decision-making[132]. - The company has established specialized committees under the board, including a strategy and sustainable development committee, to provide professional advice for decision-making[130]. - The company has implemented a risk assessment strategy that continuously collects information to identify and analyze risks, adjusting response strategies as necessary[182]. - The company has established a comprehensive internal control system, including a governance structure with a board of directors, supervisory board, and independent directors, ensuring compliance with relevant laws and regulations[178]. - The audit committee, composed of three directors, oversees internal and external audits, ensuring that at least one independent director is a qualified accounting professional[180]. Market and Industry Trends - The global pharmaceutical R&D expenditure reached $241.5 billion in 2022, with projections to grow to $394.3 billion by 2030, indicating a compound annual growth rate of 6.3%[30]. - In 2023, large pharmaceutical companies allocated 23.4% of their net sales to R&D, totaling $161 billion, a nearly 50% increase from 2018 levels[30]. - China's pharmaceutical R&D spending is projected to reach $67.5 billion by 2030, with a compound annual growth rate (CAGR) of approximately 9.5% from 2022 to 2030, nearly double the global growth rate[31]. - The number of clinical trials in China increased from 3,316 in 2022 to 4,206 in 2023, representing a year-on-year growth of 26.84%[32]. - The pharmaceutical R&D outsourcing market is expected to reach 275.77 billion RMB by 2030, growing at a CAGR of 14.0%[34]. Research and Development - The company emphasizes a patient-centered approach in its clinical trial management system, which is crucial for the pharmaceutical R&D industry[29]. - The company aims to enhance project management efficiency and improve service quality through ongoing research and development initiatives[72]. - Research and development expenses increased by 30%, totaling 150 million yuan, focusing on innovative technologies[121]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for this purpose[121]. Operational Efficiency and Management - The company has established an ERP system to enhance resource management and operational efficiency[11]. - The company has developed targeted project management systems to optimize clinical trial processes, improving quality and efficiency[40]. - The company has established a professional technical service team of over 4,000 members, ensuring efficient execution of clinical trial site management services[48]. - The company has implemented a project personnel allocation system to streamline personnel management and improve operational efficiency[70]. - The company aims to improve operational efficiency, targeting a 15% reduction in costs by the end of 2023 through process optimization[124]. Social Responsibility and ESG - The company highlights its dedication to ESG principles, evaluating sustainability and social impact[12]. - The company issued its first social responsibility report, highlighting its commitment to social responsibility and sustainable development[54]. - The company donated 300,000 yuan to support the development of the macadamia nut industry in Mengkang Village, Yunnan Province, as part of its rural revitalization efforts[193]. - The company is committed to enhancing its corporate governance and has taken steps to ensure compliance with relevant regulations[188]. Risks and Challenges - The company faces risks from potential declines in pharmaceutical R&D service market demand, which could negatively impact business and financial performance[100]. - The company is at risk of declining gross margins due to increased competition and potential inability to control costs effectively[105]. - The company must comply with GCP quality management requirements during clinical trials, which poses risks related to service quality and regulatory compliance[106]. - The company faces risks related to employee turnover, which may hinder business expansion and project execution, necessitating higher compensation and benefits to attract and retain talent[108]. Strategic Outlook - The company is actively expanding its market presence, as evidenced by its engagement with various institutional investors across multiple cities[119]. - Future outlook includes strategic planning for new product launches and technological advancements to enhance market competitiveness[120]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings[120]. - The company plans to continue its focus on core business areas while diversifying its portfolio to mitigate risks[120].

本人未在公司担任除独立董事外的其他职务，并与公司及控股股东、实际控 制人不存在直接或者间接利害关系，或者其他可能影响本人进行独立客观判断关 系。经自查，本人不存在影响独立性的情形，符合《上市公司独立董事管理办法》 《公司章程》《公司独立董事工作制度》中对独立董事独立性的相关规定。 普蕊斯（上海）医药科技开发股份有限公司 独立董事廖县生先生 2023 年度述职报告 各位股东及股东代表： 本人作为普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"） 第二届董事会和第三届董事会的独立董事，严格按照《公司法》《证券法》《上市 公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等有关法律法规以及《公司章程》《独立董事工作制度》 等的有关规定，在 2023 年度工作中，定期了解公司的财务和运营情况，忠实履 行独立董事的相关职责，积极出席公司召开的相关会议，认真仔细审阅各项会议 议案及相关材料，对董事会的相关事项发表独立意见，充分发挥独立董事的作用， 努力维护公司和全体股东特别是中小股东的合法权益。现将 2023 年度任职期间 本人履行独立董事的职责情况报告如下： 一、 ...

| 序 | 授信银行 | | 计划申请综合授信额度 | | 计划申请综合 | 综合授信 | | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | | 授信品种 | 担保措施 | | 1 | 兴业银行股份有限公司 | 不超过 | 2 | 亿元人民币 | | 信用 | | | 上海浦东支行 | 期限 | | 12 个月 | | | | 2 | 中信银行股份有限公司 | 不超过 | 2 | 亿元人民币 | | 信用 | | | 上海分行 | 期限 | | 12 个月 | 流动资金贷款、银 | | | 3 | 招商银行股份有限公司 | 不超过 | 2 | 亿元人民币 | 行承兑汇票、贸易 融资、保函、信用 | 信用 | | | 上海分行 | 期限 | | 12 个月 | | | | 4 | 中国工商银行股份有限 | 不超过 | 2 | 亿元人民币 | 证等品种 | 信用 | | | 公司上海市黄浦支行 | 期限 | | 12 个月 | | | | 5 | 上海浦东发展银行股份 | 不超过 | 2 | 亿元人民币 | | 信用 | | | 有限公司黄浦支行 | ...

普蕊斯（上海）医药科技开发股份有限公司 股东大会议事规则 公司章程附件一： 普蕊斯（上海）医药科技开发股份有限公司 股东大会议事规则 第一章 总 则 第一条 为规范公司行为，保证股东大会依法行使职权，提高股东大会议事效 率，保障股东的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》和公司章程的规定，特制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定召 开股东大会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东大会。公司全体董事应 当勤勉尽责，确保股东大会正常召开和依法行使职权。 第三条 公司应在保证股东大会合法、有效的前提下，通过各种方式和途径， 包括充分运用现代信息技术手段，扩大股东参与股东大会的比例。股东大会时间、 地点的选择应有利于尽可能多的股东参加会议。 公司召开股东大会应当平等对待全体股东，不得以利益输送、利益交换等方 式影响股东的表决，操纵表决结果，损害其他股 ...

普蕊斯（上海）医药科技开发股份有限公司 董事会战略与可持续发展委员会工作细则 普蕊斯（上海）医药科技开发股份有限公司 董事会战略与可持续发展委员会工作细则 第一章 总则 第一条 为适应公司的战略发展需要，增强公司核心竞争力，确定公司发展 规划，健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的 质量，完善公司治理结构，根据《中华人民共和国公司法》、《上市公司治理准则》、 《普蕊斯（上海）医药科技开发股份有限公司章程》（以下简称"《公司章程》"） 及其他有关规定，公司特设立董事会战略与可持续发展委员会，制定本工作细则。 普蕊斯（上海）医药科技开发股份有限公司 董事会战略与可持续发展委员会工作细则 第七条 战略与可持续发展委员会下设工作组, 由公司总经理任工作组组长。 组员根据实际工作临时组成，负责委员会的资料收集与研究、项目可行性分析、 投融资方案制订及其他日常工作。 第三章 职责权限 第二条 董事会战略与可持续发展委员会（"委员会"）是董事会按照股东大 会决议设立的专门工作机构，主要负责对公司长期发展战略和重大投资决策进行 研究并提出建议。 第二章 人员组成 第三条 战略与可持续发展委员会成员由 ...

证券代码：301257 证券简称：普蕊斯 公告编号：2024-013 普蕊斯（上海）医药科技开发股份有限公司 第三届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 普蕊斯（上海）医药科技开发股份有限公司(以下简称"公司")第三届监事会 第七次会议于 2024 年 4 月 25 日在公司会议室以现场会议及通讯相结合的形式 召开，本次会议通知及会议资料已于 2024 年 4 月 15 日以专人送达、电子邮件的 方式发出，会议应出席监事 3 人，实际参与会议的监事 3 人，其中覃德勇先生以 通讯方式出席会议。会议由监事会主席马宇平先生召集并主持，董事会秘书赖小 龙先生列席本次会议。本次会议的召集、召开符合法律、法规、部门规章、规范 性文件和《公司章程》等有关规定，会议合法有效。 二、监事会会议审议情况 与会监事认真审议，审议通过了以下议案： （一）审议通过《关于公司<2023 年度监事会工作报告>的议案》 经审议，监事会认为：《2023 年度监事会工作报告》充分反映了公司 2023 年度的监事会履职情况，内容真实、准 ...

证券代码：301257 证券简称：普蕊斯 公告编号：2024-028 普蕊斯（上海）医药科技开发股份有限公司 关于部分募集资金专户销户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 | 开户主体 | 开户银行 | 募集资金专户账号 | 募集资金 | 账户 | | --- | --- | --- | --- | --- | | | | | 用途 | 状态 | | 普蕊斯（上 | 兴业银行股份有限公司 | 216230100100296283 | 临床试验 | 本次 | | 海）医药科 | 上海浦东支行 | | 站点扩建项目 | 销户 | | 技开发股份 | 中国工商银行股份有限 | 1001235929300157751 | 补充流动资金 | 本次 | | 有限公司 | 公司上海市黄浦支行 | | | 销户 | 截至本公告披露日，公司已办理完成上述募集资金专户的注销手续，并将该 事项及时通知保荐人及保荐代表人。鉴于上述募集资金专户已注销，公司就该募 集资金专户与兴业银行股份有限公司上海浦东支行、中国工商银行股份有限公司 上海市黄 ...

Revenue and Profitability - The company's revenue for Q1 2024 was ¥184,532,679.41, representing a 17.42% increase compared to ¥157,152,422.97 in the same period last year[5]. - The net profit attributable to shareholders decreased by 10.22% to ¥22,737,202.98 from ¥25,325,308.14 year-on-year[5]. - Basic earnings per share decreased by 9.52% to ¥0.38 from ¥0.42 in the same period last year[5]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 19.57 million, reflecting a year-on-year growth of 7.74%[14]. - The total comprehensive income attributable to the parent company for Q1 2024 was ¥22,737,202.98, a decrease from ¥25,325,308.14 in Q1 2023, representing a decline of approximately 10.5%[21]. Cash Flow and Financial Position - The net cash flow from operating activities was negative at -¥8,550,816.03, a decline of 148.42% compared to ¥17,660,682.50 in the previous year[5]. - Cash inflows from operating activities totaled ¥170,027,073.63, down from ¥181,477,062.22 in the previous year, reflecting a decrease of approximately 6.5%[24]. - The net cash flow from investment activities was ¥81,122,056.14, a turnaround from a negative cash flow of -¥1,118,431.51 in Q1 2023[24]. - The total cash and cash equivalents at the end of Q1 2024 were ¥564,307,218.74, down from ¥692,603,148.66 at the end of Q1 2023, a decrease of approximately 18.5%[24]. - The company's cash and cash equivalents increased to RMB 564.31 million from RMB 493.33 million at the beginning of the period[16]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,371,068,862.97, a slight increase of 0.31% from ¥1,366,819,029.33 at the end of the previous year[5]. - Total liabilities decreased to ¥264,852,099.81 from ¥286,223,762.86 year-over-year, a reduction of 7.4%[18]. - The company reported a decrease in trading financial assets from RMB 421.14 million to RMB 340.78 million[16]. - Accounts receivable decreased from RMB 124.21 million to RMB 113.30 million[16]. - The company reported a decrease in accounts payable to ¥1,859,511.92 from ¥2,593,586.53, a decline of 28.3%[18]. Expenses and Investments - Sales expenses rose by 36.14% to ¥2,088,982.69 due to increased personnel costs and marketing activities[10]. - Research and development expenses increased to ¥8,664,189.05, compared to ¥6,857,112.53 in Q1 2023, reflecting a growth of 26.4%[20]. - Investment income surged by 204.32% to ¥2,632,521.24, primarily from gains on structured deposits[10]. - The company reported a significant increase in fair value gains of 1,291.54% to ¥784,370.99, attributed to the appreciation of structured deposits[10]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,596[12]. - The chairman and actual controller, Lai Chunbao, announced a plan to increase his shareholding by investing between RMB 5 million and RMB 8 million, successfully acquiring 160,000 shares for RMB 6.54 million[15]. Company Operations - As of the end of the reporting period, the company had a total of 4,407 employees, with over 4,200 being professional staff, serving more than 930 clinical trial institutions[14]. - The company continues to expand its service coverage, reaching over 1,300 clinical trial institutions across more than 190 cities in China[14]. - The company has undertaken over 3,100 international and domestic SMO projects, with 1,885 projects currently in execution[14]. Future Outlook - The company has not yet audited the Q1 2024 report[25]. - The company is set to implement new accounting standards starting in 2024, which may affect future financial reporting[25].

普蕊斯(上海)医药科技开发股份有限公司 2023 年度 非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市 公司的关联关 | 上市公司核 算的会计科 | 2023 | 年期初占用 资金余额 | 2023 年度占用累计发 生金额（不含利息） | 2023 | 年度占用资金 的利息(如有) | 2023 | 年度偿还累 计发生金额 | 2023 | 年期末占 用资金余额 | 占用形成原因 | | 占用性质 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 系 | 目 | | | | | | | | | | | | | | | 控股股东、实际控制人及其 | 无 | | | | | | | | | | | | | | - | | | 附属企业 | | | | | | | | | | | | | | | | | | 小计 | - | - | - | | | | | | | | | | - | ...

监事会议事规则 第一条 为完善公司法人治理结构，规范监事会的议事方式和表决程序，确 保公司监事会能够依法行使职权，维护股东、公司的合法权益，根据《中华人民 共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》《深圳 证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定以及和本公司章程等有关规定，制 订本规则。 第二条 监事会是公司依法设立的监督机构，代表全体股东对公司的经营管 理活动以及董事会、高级管理层实施监督，对股东大会负责并报告工作。 第三条 监事会由 3 名监事组成。监事由 2 名股东代表和 1 名公司职工代表 担任，股东代表担任的监事由股东大会选举产生或更换，职工代表担任的监事由 公司职工民主选举产生或更换。 普蕊斯（上海）医药科技开发股份有限公司 监事会议事规则 公司章程附件三： 普蕊斯（上海）医药科技开发股份有限公司 第四条 监事会应严格遵守《公司法》及其他法律、法规关于监事会的各项 规定，认真组织好监事会工作，履行监事会职责，维护公司利益，尤其要监督和 维护公司股东的合法权益不受损害，对全体股东及公司负有诚信及勤勉义务。 ...